U.S. markets closed

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
18.98-0.36 (-1.86%)
At close: 04:59PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.34
Bid19.01 x 0
Ask19.30 x 0
Day's Range18.93 - 20.98
52 Week Range18.93 - 109.10
Avg. Volume129,402
Market Cap663.393M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ORPHA.CO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Financial Calendar 2022

      Orphazyme A/SCompany announcement No. 26/2021www.orphazyme.comCompany Registration No. 32266355 Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial reports according to the following schedule: Deadline for submission of shareholder proposals to Annual General MeetingFebruary 23, 2022 Annual Report 2021March 15, 2022 Annual General Meeting 2022April 7, 2022 Interim R

    • GlobeNewswire

      Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen

      Orphazyme A/SCompany announcement No. 25/2021Company Registration No. 32266355 Copenhagen – November 4, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement (“Prospectus”) relating to a U.S. At-the-Market Offering Program, pursuant to which the Company may issue and sell American Depositary Shares ("ADSs") having an aggregate offering p

    • GlobeNewswire

      Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C

      Orphazyme A/SCompany announcement No. 24/2021Inside informationCompany Registration No. 32266355 Progress made in understanding potential resolution of topics outlined in Complete Response Letter, including need for additional data to support NDAFDA recommends the company provides supplemental information and analyses, and the FDA offers to have further interactions to identify a path to resubmission for arimoclomol in NPC Copenhagen – October 31, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-st